GlobeNewswire

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Share

Basel, Switzerland, April 21, 2021

Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2020.

In accordance with the ordinance issued by the Swiss Federal Council (COVID-19 Ordinance 3, extended until December 31, 2021) and the protective measures against the coronavirus that currently apply, the board of directors of Basilea Pharmaceutica Ltd. had decided to hold the AGM 2021 without the physical presence of shareholders. Accordingly, shareholders exercised their voting rights exclusively via the independent proxy. At the AGM, a total of 3,997,434 shareholder votes, equivalent to 30.9 percent of the share capital and 53.5 percent of the shares entitled to vote, were represented by the independent proxy.

Domenico Scala, Chairman, commented: “We thank our shareholders for the broad support of the proposed motions. We regret that due to the ongoing coronavirus pandemic we again had to run our AGM without the physical presence of shareholders, but hope that we will be able to hold the AGM 2022 under normal circumstances and again welcome our shareholders in person.”

At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2020. They also endorsed carrying forward the accumulated deficit and approved the discharge of the members of the board of directors and the management committee.

Domenico Scala was re-elected as Chairman and Dr. Martin Nicklasson, Dr. Nicole Onetto, Ronald Scott, Steven D. Skolsky and Dr. Thomas Werner were re-elected as members of the board of directors. In addition, Dr. Nicklasson and Dr. Werner were re-elected and Dr. Onetto was newly elected to the compensation committee. The term of all board members lasts until the end of the AGM 2022.

The shareholders also approved the proposed maximum aggregate amount of compensation for the board of directors for the period to the AGM 2022, and the maximum aggregate amount of compensation for the management committee for the financial year 2022. In a non-binding advisory vote, the shareholders endorsed the compensation report for the financial year 2020.

The shareholders also approved the proposed amendment of the articles of association to renew the authorization of the board of directors to increase the share capital by a maximum of CHF 1’000’000.-- by issuing a maximum of 1’000’000 registered shares having a nominal value of CHF 1.-- each until April 2023.

Finally, the shareholders re-elected Dr. Caroline Cron as independent proxy until the end of the next AGM and re-elected PricewaterhouseCoopers Ltd, Basel, as auditors for the financial year 2021.

At the time of the AGM, 64.9 percent of the share capital were registered in Basilea’s share register.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone+41 61 606 1102
E-mailmedia_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Underskott för staten i april 20217.5.2021 09:30:00 CEST | Pressemelding

Underskott för staten i april 2021 Statensbetalningar resulterade i ett underskott på 16,9miljarder kronor i april. Riksgäldens prognosvar ett underskottpå 24,9 miljarder kronor.Statens skatteinkomster var något högre än förväntat samtidigt som Riksgäldens nettoutlåning var lägre. Det primära saldot var 5,4 miljarder kronor högre än prognos. Det beror främst på att skatteinkomsterna var cirka 4 miljarder kronor högre än beräknat. Riksgäldens nettoutlåning till myndigheter m.fl. var 3,5 miljarder kronor lägre än prognos. Det beror på högre inlåning från ett antal myndigheter. Räntebetalningarna på statsskulden var 0,8 miljarder kronor högre än prognos. För tolvmånadersperioden till och med april 2021 visade statens betalningar ett underskott på 148,1 miljarder kronor. Statsskulden uppgick till 1 226 miljarder kronor i slutet av april. Utfallet för maj 2021 publiceras den 7 juni kl. 09.30. Nya prognoser för 2021 och 2022 publiceras den 27 maj, kl. 09.30. Kontakt Pressfunktionen, 08 613 4

Deficit for Swedish central government in April 20217.5.2021 09:30:00 CEST | Press release

Deficitfor Swedish central government in April2021 Swedish central government payments resulted in a deficitof SEK 16.9 billion inApril. The Debt Office's forecast was a deficitof SEK 24.9 billion.Central government tax income were slightly higher than expected, while the Debt Office's net lending was lower. The primary balance was SEK 5.4 billion higher than the forecast. This was mainly due to tax income being approximately SEK 4 billion higher than calculated. The Debt Office’s net lending to government agencies etc. was SEK 3.5 billion lower than forecasted. This is explained by higher deposits by a number of government agencies. Interest payments on central government debt were SEK 0.8 billion higher than the forecast. For the twelve-month period up to the end of April 2021, central government payments resulted in a deficit of SEK 148.1 billion. Central government debt amounted to SEK 1 226 billion at the end of April. The outcome for May 2021 will be published on June 7 at 9.30 a

Nexstim Receives a New NBS System Order from a Leading California Based Academic Hospital7.5.2021 09:00:00 CEST | Press release

Press release,Helsinki, 7.5.2021 at 10:00 AM(EEST) Nexstim Receives a New NBS System Order from a Leading California Based AcademicHospital Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received an NBS system order from a distinguished academic hospital based in Northern California, US. Nexstim NBS systems use the unique SmartFocus® TMS technology that enables accurate stimulation of the targeted area in the brain. The Nexstim NBS system is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain. Mikko Karvinen, CEO of Nexstim, says: “We are happy to announce the sale of this new NBS system to a renownedacademic hospital. The NBS business has been a stable source of revenue for us during the COVID-19 pandemic, and we are glad to see an increasing number of patients benefiting from our SmartFocus® TMS technology as the system will be used for motor a

HOYLU MOTTAGER ORDER FRÅN STOR BYGGFIRMA I USA7.5.2021 08:45:00 CEST | Pressemelding

Stockholm den 7 maj 2021 – Hoylu, ledande inom visuella samarbetslösningar för distribuerade team, meddelade idag att man fått en order från Barton Malow, (www.bartonmalow.com), ett fullservice entreprenad företag med huvudkontor i Michigan, USA. Ordervärdet uppgår till 340 000 sek och representerar expansionen av Hoylus verksamhet inom byggbranschen med high-end arkitektonisk design och projektledning. För ytterligare information, vänligen kontakta: Stein Revelsby, VD på Hoylu + 1 213 440 2499 e-post: sr@hoylu.com Karl Wiersholm, CFO på Hoylu + 1 425 829 2316 e-post: kw@hoylu.com Om Hoylu Hoylus uppdrag är att göra distansarbete och informationsutbyte enkelt. Genom vår anpassningsbara Connected Workspaces™ levererar vi programvarulösningar till företag, organisationer och individer i praktiskt taget alla branscher som gör det möjligt för alla team, stora som små att arbeta effektivt och säkert i ett intuitivt och enkelt arbetsflöde. För mer information: www.hoylu.com Testa Hoylu grati

HOYLU RECEIVES ORDER FROM LARGE CONSTRUCTION FIRM IN THE US7.5.2021 08:45:00 CEST | Press release

Stockholm, Sweden, May 7, 2021 – Hoylu, a leader in visual collaboration solutions for distributed teams, announced today that it has received an order from Barton Malow, (www.bartonmalow.com), a full-service construction firm headquartered in Michigan, US. The order value is 340,000 SEK and represents an expansion of Hoylu’s business within the construction industry with high-end architectural design and project management. For more information, please contact: Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.com Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.com About Hoylu Hoylu’s mission is to empower distributed teams to collaborate easily and seamlessly while always staying in sync. Hoylu’s Connected Workspaces™ helps enterprises as well as small and medium companies run projects, programs, and initiatives across time zones and continents with the same level of engagement and clarity as if everyone were working in the same room. For more information: www

Dlab partner in European digital transformation project for a more sustainable energy system7.5.2021 08:30:00 CEST | Press release

Cleantech company Dlaboratory Sweden AB (publ) joins a European consortium in applying for funds from EU’s joint programming platform ERA-NET Smart Energy Systems (SES) for a project on power grid resilience. The overall aim of the project is to advance the green energy transition in all sectors of the energy system while also ensuring security of supply in the power grid. Swedish KTH Royal Institute of Technology, Austrian Institute of Technology (AIT), Siemens, Wiener Netze, Fraunhofer ISE, OFFIS, and Solandeo GmbH join forces with dLab for the ERA-Net SES call for transnational projects on digital transformation for green energy transition. The proposed project called Resili8 – Resilience for Cyber-Physical Energy Systems – is aiming to increase grid resilience through a digitalized smart system. Part of the project proposal plan is an installation of dLabs solution in Austrian utilities company Wiener Netze’s power grid to study improved resilience possibilities. - The future energ

Yara International ASA ex-dividend NOK 20 today7.5.2021 08:01:00 CEST | Press release

Oslo, 7 May 2021: Shares in Yara International ASA will be traded ex-dividend NOK 20 as of today, 7 May 2021. Contact Thor Giæver, Investor Relations Cellular: (+47) 480 75 356 E-mail: thor.giaver@yara.com About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger and a planet respected, we pursue a strategy of sustainable value growth, promoting climate-friendly crop nutrition and zero-emission energy solutions. Yara’s ambition is focused on growing a climate positive food future that creates value for our customers, shareholders and society at large and delivers a more sustainable food value chain. To achieve our ambition, we have taken the lead in developing digital farming tools for precision farming, and work closely with partners throughout the food value chain to improve the efficiency and sustainability of food production. Through our focus on clean ammonia production, we aim to enable the hydrogen econo